Genta, Inc (fka GNTAQ)

[The Holder]

ENOUGH REACHING ON THE WEBSITE.

Seriously, let's stick to the facts here.

Genasense is providing incredible confirmatory data of a prior phase III trial in its late phase III Agenda Trial.

Now THAT is something to be excited about. I mean, really effin' excited. The data is and will continue to exceed expectations with respect to confirming prior positive results and will ULTIMATELY lead to the approval and world-wide application of Genasense in the treatment of Melanoma.

I don't know and don't care about the website and why it's down. It likely has little to absolutely nothing to do with anything we'd be interested in. What does interest me is the data from the Agenda trial.